REGARDING RESTRICTED SHARES: From Mudcat18 (Mudcat, if

New Post Public Reply Private Reply Replies (2) Message Board
Neuronal Japple #14598
REGARDING RESTRICTED SHARES:

From Mudcat18 (Mudcat, if you have updated thoughts, please chime in): Many of the restricted shares that are listed on the filing were issued because of debt conversion and debt pay-off. While they were issued on the date stated in the filing, the 12-month restricted period starts not when they are issued, but rather when the debt was originally incurred. Let's actually read the filing and do a little math...

As of Dec. 31, 2013:
O/S = 3,417,417,549
Float = 2,295,374,724

That leaves 1,122,042,825 of the O/S unaccounted for.

In the filing, 804,484,675 were issued between March 2013 and September 2013 for things like services and those are definitely off restricted status in 2014. That said, 203,000,000 belong to Bill and Jeff who can only sell a combined 52,000,000 as insiders.

We are down to 317,558,150 of the O/S unaccounted for.

In the filing, 1,730,744,376 were issued in the same period for debt conversion and debt pay-off. Therefore, 1,413,186,226 of these shares must have made their way into the float and have been absorbed by the market. Given what we have seen in January and February, I am guessing that a good deal of the remaining 317.5 million shares have made there way to Float as well.

Therefore, the question is what is going to happen with the 804.5 million shares that are coming off restricted status. The timeline for these is as follows:

March 83,240,980
April 94,000,000
May 240,243,695
June 0
July 247,000,000
August 140,000,000

In my opinion, those number seems like they will be fairly easily absorb by the market considering the license will be place by the time the bulk of them come to market.

FURTHER INFO ON RESTRICTED SHARES:

Creative Edge Nutrition/Bill Chaaban (1/14/14):
"...And for those who worry about the share structure, most shares could have had their share restrictions removed and been sold by now... Some almost a year ago. These people see the bigger picture and most are in for the long haul. The share structure from the financials are already factored in. Restricted certs have a one year hold. And on average a 3 to 6 month deposit time."

Creative Edge Nutrition Inc. (FITX) Stock Research Links

FITX Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Top 5 Most Recently Viewed Articles

Understanding Adobe’s Recent Options Activity Results

Updated Category News Views 114

Adobe's Options Activity Highlights In the world of finance, significant trades often signal important market sentiments. Recently, major investors have moved toward a bearish outlook on Adobe. Analyzing the options history for Adobe (NASDAQ: ADBE), we've identified a total of 67 significant trades. Our insights reveal that approximately 41% of these trades have been...

Continue Reading
Indonesia's Ongoing Challenge with Chinese Maritime Presence

Updated Category News Views 130

Indonesia's Maritime Security Efforts Intensify Recently, Indonesia's maritime security has been under increased scrutiny as incidents involving a Chinese coast guard vessel continue to escalate. This week, a Chinese vessel was driven from Indonesian waters not once, but twice, after interfering with a critical energy survey conducted by Pertamina, the state energy...

Continue Reading
Revolutionizing Game Development with Upheaval Games' Dreamer Portal

Updated Category News Views 140

Welcome to the Future of Game Development Upheaval Games, founded by veterans from the gaming industry, embraces a new frontier in game design with the introduction of The Dreamer Portal. This innovative web-based interface allows creators to effortlessly build immersive game content with just a simple prompt. Imagine the power of crafting unique creatures, items, and...

Continue Reading
Alvotech Moves Forward with Gobivaz® Approval in Europe

Updated Category News Views 190

Alvotech and Advanz Pharma Collaborate for Biosimilar Approval REYKJAVIK and LONDON – Alvotech (NASDAQ: ALVO), a renowned biotechnology firm, along with Advanz Pharma, a leading global pharmaceutical company, has shared important news regarding the marketing approval of Gobivaz®, a proposed biosimilar to Simponi® (golimumab). This biologic treatment is designed for...

Continue Reading
Exploring the Growth Potential of Remote Patient Monitoring Sector

Updated Category News Views 181

Remote Patient Monitoring Set for Dynamic Growth The increasing prevalence of chronic conditions worldwide is expected to significantly accelerate the growth of the remote patient monitoring (RPM) market. As conditions like hypertension, diabetes, and cardiovascular diseases become more common, coupled with an aging population, healthcare systems face immense pressure to...

Continue Reading